EDAP TMS S.A.(FOCL)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$3.25
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for FOCL

11/13/2026: FOCL (1-star) is currently NOT-A-BUY. Pass it for now.

EDAP TMS S.A. is a medical technology company specializing in robotic high-intensity focused ultrasound systems for non-invasive urological care. The company's primary strength is its flagship Focal One platform, which benefits from rising clinical adoption and a growing base of recurring revenue streams. Its core growth opportunity lies in expanding procedural adoption and advancing clinical trials into new indications like BPH and endometriosis. However, the company faces ongoing financial and execution risks, including persistent net operating losses and intense competition from much larger medical device conglomerates. This stock is best suited for growth-oriented investors willing to monitor hospital adoption rates and regulatory progress closely.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitEDAP offers direct exposure to expanding robotic healthcare adoption and rapid top-line scaling in focal ultrasound technology.
Momentum investorStrong fit while signal remains positiveThe stock frequently reacts strongly to clinical data readouts, regulatory approvals, and quarterly sales milestones.
Value investorWeak fitThe company currently lacks consistent profitability and positive net income, trading primarily on future growth prospects.
Dividend investorWeak fitEDAP does not pay dividends, retaining all earnings to fund commercialization and R&D.
Low-risk investorWeak fitSmall-cap clinical-stage or early-commercial medical device equities carry high regulatory, execution, and financial volatility.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighSmall-cap biotechnology and medical device stocks experience sharp price fluctuations based on sentiment and news flow.
Valuation riskMedium / highValuation relies heavily on long-term multi-year revenue projections rather than near-term earnings or cash flow.
Competition risk (robotics and alternative therapies)HighThe company competes with entrenched medical device giants possessing vastly superior capital and distribution networks.
Business qualityMediumProprietary medical technology provides a defensive moat, though lack of net profitability limits immediate financial quality scores.
Dividend incomeLow / noneNo dividend distributions are paid to shareholders.
Execution riskHighSuccess depends entirely on hospital adoption rates, physician training, and expanding reimbursement for Focal One.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 153.23M USD
Price to earnings Ratio -
1Y Target Price 8.3
Price to earnings Ratio -
1Y Target Price 8.3
Volume (30-day avg) 59.2K shares
Beta -0.02
52 Weeks Range 1.95 - 6.40
Updated Date 11/15/2026
52 Weeks Range 1.95 - 6.40
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -1.35

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Distribution

BUY participation
100.0%
Active BUY / eligible
3 / 3
30-Day BUY Count Change
+2

Eligible universe: 3 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Rolling Over
PRICE PATH

Rolling Over

The price momentum is slowing down and beginning to turn downward.

Choppy
PRICE STABILITY

Choppy

The stock has experienced frequent reversals and pronounced short-term price swings.

Analysis of Past Performance

Type Stock
Historic Profit 8.06%
Avg. Invested days 28
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 2.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
FOCL receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
FOCL has moderate overall fundamentals (3 stars), with soft financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-42.6%), weak cash generation (FCF margin -30.3%), moderate revenue growth (+2.0%).

Financial Health Rating

★★★★★
FOCL's financial health is soft, with the relatively strongest area being moderate liquidity, including working-capital and asset support (WC/assets 25.3%). Profitability is soft (2 stars), which helps explain the 2-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is FOCL's strongest growth driver at +2.0% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while earnings growth (-42.6%, negative) and free-cash-flow growth (-32.8%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 40.3% and approximately 72.1% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 5.38% supports management-shareholder alignment.

Top 5 Institutional Investors

Soleus Capital Management, L.P. 15.48%
Morgan Stanley - Brokerage Accounts 7.07%
FLAX POND CAPITAL, LLC 3.23%
Rock Springs Capital Management LP 2.94%
Bruce & Co Inc 0.93%

Unit Economics (Per $1K Revenue)

★★★★★
FOCL generates approximately $425 of gross profit, $-356 of operating income, and $-303 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.24% (Tax Credit)

Quantitative Style Profile

★★★★★
FOCL has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
HIFU Systems & TreatmentsSales and operating leases of Focal One robotic units, treatment fees, and related single-use disposables.This is the core engine driving future growth and high-margin recurring streams.
HIFU Maintenance ServicesAnnual service contracts and technical support for installed Focal One systems.Provides predictable, recurring maintenance revenue as the global install base grows.
ESWL & Distribution ServicesLegacy lithotripsy parts and distribution of third-party medical lasers and micro-ultrasound systems.Serves as a secondary revenue contributor while the company transitions fully to its focal therapy focus.
Geographic Exposure (US & International)Commercial operations spanning the United States, Europe, and international markets via direct sales and local partners.U.S. hospital expansion and reimbursement trends dictate overall revenue acceleration.

Valuation

Trailing PE -
Forward PE 38.91
Enterprise Value 134.79M
Price to Sales(TTM) 1.88
Enterprise Value 134.79M
Price to Sales(TTM) 1.88
Enterprise Value to Revenue 1.66
Enterprise Value to EBITDA 1165.78
Shares Outstanding 47.22M
Shares Floating 34.07M
Shares Outstanding 47.22M
Shares Floating 34.07M
Percent Insiders 5.38
Percent Institutions 40.32

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.